header logo en


10 facts web



Atezolizumab (MPDL3280A) in Combination With Bevacizumab Versus Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma
 Last updated: April 09, 2018
 STATUS: Ongoing, not recruiting (per ClinicalTrials.gov/NCT02420821)


is the trial for?

Patients with kidney cancer (Renal cell carcinoma, RCC) who currently meet the following criteria:

  • clear-cell component
  • advanced and/or metastatic disease
  • no previous systemic or experimental treatment for RCC
  • overall health status has to be good (ECOG 0 or 1) with adequate blood and organ function


is the key question that this trial is attempting to answer?

This phase-III study seeks to clarify whether the new immunotherapies are superior to one of the standard therapies for kidney cancer.

It investigates the immune-checkpoint inhibitor atezolizumab (MPDL3280A) plus bevacizumab versus sunitinib alone in patients with inoperable, locally advanced, or metastatic renal cell carcinoma (RCC).


patients might want to participate?

This clinical trial offers patients an opportunity to access a new therapy that may be effective for kidney cancer. This trial will further support the research in kidney cancer and potentially help other patients with kidney cancer. The trial might or might not have benefit in your individual case. For more about the importance and benefits of joining clinical trials, please click here.


will the trial be open?

The study is open (currently recruiting) – 900 patients worldwide are currently expected to participate.


is the trial available?

The trial will be available in 166 cancer centers worldwide.
For a complete list of trial locations, please click here For a complete list of trial locations, please click here:  Trial locations IMmotion151



What does the study look like?

There will be 2 study arms (groups): all participating patients will be randomly divided (by a computer) in two groups. Please note that patients in both groups will receive an active medication. No patient receives a placebo.

Patients in one group will be assigned bevacizumab (Avastin™) in combination with atezolizumab (MPDL3280A). Patients in the other group will be treated with sunitinib (Sutent™), which is an approved treatment for RCC.
  • bevacizumab (Avastin™) is a monoclonal antibody targeting VEGF, already approved for the treatment of metastatic RCC
  • atezolizumab (MPDL3280A) is a fully human monoclonal antibody targeting PDL-1
  • sunitinib (Sutent™) is an oral, small-molecule, multi-targeted receptor tyrosine kinase inhibitor, already approved for the treatment of metastatic RCC
Design MPDL3280A Bevacizumab

1) Bevacizumab + atezolizumab (MPDL3280A)
15 mg/kg bevacizumab is given intravenously in combination with a dose of 1200 mg atezolizumab (MPDL3280A) intravenously on days 1 and 22 of each 42-day cycle. Ongoing until loss of clinical benefit, unacceptable toxicity, or symptomatic deterioration attributed to disease progression

2) Sunitinib:
Sunitinib is taken by mouth once daily for 4 weeks then 2 weeks off, continuously until documented disease progression, discontinuation due to toxicity, or withdrawal of consent.


do I get more information?

Patient organisations supporting kidney cancer patients in your country may offer additional information about the trial, current recruitment status, and key contacts. Click here for a list of patient organisations serving kidney cancer patients. If there are no such organisations in your country, please email us for more information: This email address is being protected from spambots. You need JavaScript enabled to view it.


with other patients on this trial

If you want to connect with other patients considering or participating in this trial, you can find them here: List of organisations worldwide.


your experience 

You want to share your experience on this trial?
Send us an e-mail to: This email address is being protected from spambots. You need JavaScript enabled to view it.
Note that your experience would be helpful for other patients and patient organisations.


of the study

No results are available at this time. Future results will be linked here.
Disclaimer: This is a patient-friendly summary of the clinical trial which has been provided for informational purposes only. Patients should consult their physician about any clinical trial opportunity.